10 reasons why you should use azithromycin
Article Sidebar
Published:
Jun 30, 2015
Keywords:
azithromycin, antibiotic
Main Article Content
Abstract
Azithromycin is a improved macrolide antibiotic. This preparation has a unique pharmacokinetic properties of achieving very high concentrations in the tissues. The drug is well tolerated by patients, and a short and convenient therapy increases the number of patients who complete doctor’s recommendation in its entirety. Azithromycin next preferred antibacterial action also has anti-inflammatory properties and beneficial effect on the functioning of the immune systems.
Downloads
Download data is not yet available.
Article Details
How to Cite
Ratajczak , J. (2015). 10 reasons why you should use azithromycin. Alergoprofil, 11(2), 11-16. Retrieved from https://journalsmededu.pl/index.php/alergoprofil/article/view/832
Issue
Section
Article
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Pechere J.C.: New perspectives on macrolide antibiotics. Int. J. Antimicrob. Agents 2001; 18(supl. 1): 93-97.
2. Dzierżanowska D., Jurkiewicz D., Zielnik-Jurkiewicz B.: Zakażenia w otolaryngologii. α-medica press, Bielsko-Biała 2002: 240-250.
3. Dzierżanowska D., Dzierżanowska-Fangrat K.: Przewodnik antybiotykoterapii 2011. α-medica press, Bielsko-Biała 2011: 80-82.
4. Chazan R.: Zasady racjonalnej antybiotykoterapii. W: Chazan R. (red.): Pneumonologia i alergologia. α-medica press, Bielsko-Biała 2011: 123-130.
5. Gilbert D.N., Chambers H.F., Eliopoulos G.M. et al.: Przewodnik terapii przeciwdrobnoustrojowej Sanforda 2014. Kraków 2014.
6. Pitsouni E., Iavazzo C., Athanasiou S., Falagas M.E.: Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 2007; 30(3): 213-221.
7. Lanjouw E., Ossewaarde J.M., Stary A. et al.: 2010 European guideline for the management of Chlamydia trachomatis infection. International Journal of Std & Aids 2010; 21(11): 729-737.
8. Horner P.J., Caul E.O.: Wytyczne postępowania w zakażeniu dróg moczowo-płciowych przez Chlamydia trachomatis (AGUM/MSSVD clinical effectiveness guideline for the management of Chlamydia trachomatis genital tract infection). Medycyna Praktyczna 2003; 3: 15-161.
9. Gaciong Z., Kuna P.: Adherence, compliance, persistence – współpraca, zgodność i wytrwałość – podstawowy warunek sukcesu terapii. Medycyna po Dyplomie 2008; supl. 03/08: 2-3.
10. Parnham M.J., Erakovic Haber V., Giamarellos-Bourboulis E.J. et al.: Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol. Ther. 2014; 143(2): 225-245.
11. Drzewiecki A.: Azytromycyna mikrosferyczna w leczeniu zakażeń. Zakażenia 2010; 10(3): 55-56.
12. Kawamura-Sato K., Iinuma Y., Hasegawa T. et al.: Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aureginosa and Proteus mirabilis. Antimicrob. Agents Chemother. 2000; 44(10): 2869-2872.
13. Spagnolo P., Fabbri L.M., Bush A.: Long-term macrolide treatment for chronic respiratory disease. Eur. Respir. J. 2013; 42(1): 239-251.
14. Jaffé A., Bush A.: Anti-inflammatory effects of macrolides in lung disease. Pediatr. Pulmonol. 2001; 31(6): 464-473.
15. Postuła M.: Właściwości przeciwzapalne makrolidów. Mag. Otorynolaryng. 2007; 6(3): 67-74.
16. Kohri K., Tamaoki J., Kondo M. et al.: Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. Eur. Respir. J. 2000; 15(1): 62-67.
17. Müller O.: Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J. Antimicrob. Chemother. 1993; 31(supl. E): 137-146.
18. Zuckerman J.M., Qamar F., Bono B.R.: Macrolides, ketolides and glycylcylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect. Dis. Clin. North Am. 2009; 23(4): 997-1026.
19. Culić O., Eraković V., Cepelak I. et al.: Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur. J. Pharmacol. 2002; 450(3): 277-289.
20. Rubin B.K.: The pharmacologic approach to airway clearance: mucoactive agents. Respir. Care 2002; 47(7): 818-822.
21. Fiese E.F., Steffen S.H.: Comparison of the acid stability of azithromycin and erythromycin A. J. Antimicrob. Chemother. 1990; 25(supl. A): 39-47.
22. Foulds G., Luke D.R., Teng R. et al.: The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J. Antimicrob. Chemother. 1996; 37(supl. C): 37-44.
23. Langtry H.D., Balfour J.A.: Azithromycin. A review of its use in paediatric infectious diseases. Drugs 1998; 56(2): 273-297.
24. Treadway G., Pontani D.: Paediatric safety of azithromycin: worldwide experience. J. Antimicrob. Chemother. 1996; 37(supl. C): 143-149.
25. Bartkowiak-Emeryk M., Emeryk A.: Zakażenia chlamydiowe układu oddechowego u dzieci. Alergia 2002; 4(15): 14-17.
26. Doniec Z.: Zakażenia atypowe u dzieci. Przew. Lek. 2009; 12(6): 15.
27. Waites K.B., Talkington D.F.: Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev. 2004; 17(4): 697-728.
28. Diederen B.M.: Legionella spp. and Legionnaires’ disease. J. Infect. 2008; 56(1): 1-12.
2. Dzierżanowska D., Jurkiewicz D., Zielnik-Jurkiewicz B.: Zakażenia w otolaryngologii. α-medica press, Bielsko-Biała 2002: 240-250.
3. Dzierżanowska D., Dzierżanowska-Fangrat K.: Przewodnik antybiotykoterapii 2011. α-medica press, Bielsko-Biała 2011: 80-82.
4. Chazan R.: Zasady racjonalnej antybiotykoterapii. W: Chazan R. (red.): Pneumonologia i alergologia. α-medica press, Bielsko-Biała 2011: 123-130.
5. Gilbert D.N., Chambers H.F., Eliopoulos G.M. et al.: Przewodnik terapii przeciwdrobnoustrojowej Sanforda 2014. Kraków 2014.
6. Pitsouni E., Iavazzo C., Athanasiou S., Falagas M.E.: Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 2007; 30(3): 213-221.
7. Lanjouw E., Ossewaarde J.M., Stary A. et al.: 2010 European guideline for the management of Chlamydia trachomatis infection. International Journal of Std & Aids 2010; 21(11): 729-737.
8. Horner P.J., Caul E.O.: Wytyczne postępowania w zakażeniu dróg moczowo-płciowych przez Chlamydia trachomatis (AGUM/MSSVD clinical effectiveness guideline for the management of Chlamydia trachomatis genital tract infection). Medycyna Praktyczna 2003; 3: 15-161.
9. Gaciong Z., Kuna P.: Adherence, compliance, persistence – współpraca, zgodność i wytrwałość – podstawowy warunek sukcesu terapii. Medycyna po Dyplomie 2008; supl. 03/08: 2-3.
10. Parnham M.J., Erakovic Haber V., Giamarellos-Bourboulis E.J. et al.: Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol. Ther. 2014; 143(2): 225-245.
11. Drzewiecki A.: Azytromycyna mikrosferyczna w leczeniu zakażeń. Zakażenia 2010; 10(3): 55-56.
12. Kawamura-Sato K., Iinuma Y., Hasegawa T. et al.: Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aureginosa and Proteus mirabilis. Antimicrob. Agents Chemother. 2000; 44(10): 2869-2872.
13. Spagnolo P., Fabbri L.M., Bush A.: Long-term macrolide treatment for chronic respiratory disease. Eur. Respir. J. 2013; 42(1): 239-251.
14. Jaffé A., Bush A.: Anti-inflammatory effects of macrolides in lung disease. Pediatr. Pulmonol. 2001; 31(6): 464-473.
15. Postuła M.: Właściwości przeciwzapalne makrolidów. Mag. Otorynolaryng. 2007; 6(3): 67-74.
16. Kohri K., Tamaoki J., Kondo M. et al.: Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. Eur. Respir. J. 2000; 15(1): 62-67.
17. Müller O.: Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J. Antimicrob. Chemother. 1993; 31(supl. E): 137-146.
18. Zuckerman J.M., Qamar F., Bono B.R.: Macrolides, ketolides and glycylcylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect. Dis. Clin. North Am. 2009; 23(4): 997-1026.
19. Culić O., Eraković V., Cepelak I. et al.: Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur. J. Pharmacol. 2002; 450(3): 277-289.
20. Rubin B.K.: The pharmacologic approach to airway clearance: mucoactive agents. Respir. Care 2002; 47(7): 818-822.
21. Fiese E.F., Steffen S.H.: Comparison of the acid stability of azithromycin and erythromycin A. J. Antimicrob. Chemother. 1990; 25(supl. A): 39-47.
22. Foulds G., Luke D.R., Teng R. et al.: The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J. Antimicrob. Chemother. 1996; 37(supl. C): 37-44.
23. Langtry H.D., Balfour J.A.: Azithromycin. A review of its use in paediatric infectious diseases. Drugs 1998; 56(2): 273-297.
24. Treadway G., Pontani D.: Paediatric safety of azithromycin: worldwide experience. J. Antimicrob. Chemother. 1996; 37(supl. C): 143-149.
25. Bartkowiak-Emeryk M., Emeryk A.: Zakażenia chlamydiowe układu oddechowego u dzieci. Alergia 2002; 4(15): 14-17.
26. Doniec Z.: Zakażenia atypowe u dzieci. Przew. Lek. 2009; 12(6): 15.
27. Waites K.B., Talkington D.F.: Mycoplasma pneumoniae and its role as a human pathogen. Clin. Microbiol. Rev. 2004; 17(4): 697-728.
28. Diederen B.M.: Legionella spp. and Legionnaires’ disease. J. Infect. 2008; 56(1): 1-12.